Lipoprotein-associated phospholipase A 2 activity is associated with large-artery atherosclerotic etiology and recurrent stroke in TIA patients

Cerebrovascular Diseases

Volumn 33, Issue 2, 2012, Pages 150-158

  Delgado, Pilar ^a   Chacón, Pilar ^b   Penalba, Anna ^a   Pelegri, Dolors ^b   García Berrocoso, Teresa ^a   Giralt, Dolors ^a   Santamarina, Estevo ^b   Ribó, Marc ^b   Maisterra, Olga ^b   Alvarez Sabín, José ^b   Rosell, Anna ^a   Montaner, Joan ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Atherosclerosis; Phospholipase; Stroke, recurrent; Transient ischemic attack, outcome

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE;

AGED; ARTICLE; BRAIN ATHEROSCLEROSIS; CARDIOVASCULAR RISK; COLORIMETRY; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; FOLLOW UP; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENT DISEASE; STROKE; TRANSIENT ISCHEMIC ATTACK;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AGED; AGED, 80 AND OVER; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; COLORIMETRY; FEMALE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHOSPHOLIPASES A2; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; SPAIN; STROKE; TIME FACTORS;

EID: 83455230853     PISSN: 10159770     EISSN: 14219786     Source Type: Journal    
DOI: 10.1159/000334193     Document Type: Article

References (29)

1. Giles MF, Rothwell PM: Risk of stroke early after transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol 2007; 6: 1063-1072. (Pubitemid 350116693)
2. Wu CM, McLaughlin K, Lorenzetti DL, Hill MD, Manns BJ, Ghali WA: Early risk of stroke after transient ischemic attack: a systematic review and meta-analysis. Arch Intern Med 2007; 167: 2417-2422. (Pubitemid 350258447)
3. de Lau LM, den Hertog HM, van den Herik EG, Koudstaal PJ: Predicting and preventing stroke after transient ischemic attack. Expert Rev Neurother 2009; 9: 1159-1170.
4. Shah KH, Metz HA, Edlow JA: Clinical prediction rules to stratify short-term risk of stroke among patients diagnosed in the emergency department with a transient ischemic attack. Ann Emerg Med 2009; 53: 662-673.
5. Perry JJ, Sharma M, Sivilotti MLA, Sutherland J, Symington RN, Worster A, Émond M, Stotts G, Jin AY, Oczkowski WJ, Sahlas DJ, Murray HE, MacKey A, Verreault S, Wells GA, Stiell IG: Prospective validation of the ABCD2 scores for patients in the emergency department with transient ischemic attack. CMAJ 2011; 183: 1137-1145.
6. Redgrave JN, Coutts SB, Schulz UG, Briley D, Rothwell PM: Systematic review of associations between the presence of acute ischemic lesions on diffusion-weighted imaging and clinical predictors of early stroke risk after transient ischemic attack. Stroke 2007; 38: 1482-1488. (Pubitemid 46684149)
7. Cucchiara BL, Messe SR, Sansing L, Mac- Kenzie L, Taylor RA, Pacelli J, Shah Q, Kasner SE: Lipoprotein-associated phospholipase A2 and C-reactive protein for risk-stratification of patients with TIA. Stroke 2009; 40: 2332-2336.
8. Purroy F, Montaner J, Molina CA, Delgado P, Arenillas JF, Chacon P, Quintana M, Álvarez- Sabin J: C-reactive protein predicts further ischemic events in transient ischemic attack patients. Acta Neurol Scand 2007; 115: 60-66. (Pubitemid 44915500)
9. Rothwell PM, Howard SC, Power DA, Gutnikov SA, Algra A, van Gijn J, Clark TG, Murphy MF, Warlow CP: Fibrinogen concentration and risk of ischemic stroke and acute coronary events in 5113 patients with transient ischemic attack and minor ischemic stroke. Stroke 2004; 35: 2300-2305. (Pubitemid 39311253)
10. Shenhar-Tsarfaty S, Ben Assayag E, Bova I, Shopin L, Fried M, Berliner S, Shapira I, Bornstein NM: Interleukin-6 as an early predictor for one-year survival following an ischaemic stroke/transient ischaemic attack. Int J Stroke 2010; 5: 16-20.
11. Gorelick PB: Lipoprotein-associated phospholipase A2 and risk of stroke. Am J Cardiol 2008; 101: 34F-40F.
12. Mannheim D, Herrmann J, Versari D, Gossl M, Meyer FB, McConnell JP, Lerman LO, Lerman A: Enhanced expression of Lp- PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques. Stroke 2008; 39: 1448-1455.
13. Special report from the National Institute of Neurological Disorders and Stroke. Classification of cerebrovascular diseases III. Stroke 1990; 21: 637-676.
14. Ley-Pozo J, Ringelstein EB: Noninvasive detection of occlusive disease of the carotid siphon and middle cerebral artery. Ann Neurol 1990; 28: 640-647. (Pubitemid 20373897)
15. Adams HP Jr., Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd: Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24: 35-41.
16. Johnston SC, Rothwell PM, Nguyen-Huynh MN, Giles MF, Elkins JS, Bernstein AL, Sidney S: Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet 2007; 369: 283-292. (Pubitemid 46136488)
17. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Chambless LE, Myerson M, Wu KK, Sharret AR, Boerwinkle E: Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med 2005; 165: 2479-2484. (Pubitemid 41720009)
18. Elkind MS, Tai W, Coates K, Paik MC, Sacco RL: High-sensitivity C-reactive protein, lipoprotein- associated phospholipase A2, and outcome after ischemic stroke. Arch Intern Med 2006; 166: 2073-2080. (Pubitemid 44631394)
19. Furie KL, Parides MK, Greer DM, Camargo ECS, Singhal AB, Lederer M, Hagan N, Dipietro A, Bliss S, McCarthy CJ, Kistler JP, Kelly PJ: Lipoprotein- associated phospholipase A2 activity predicts early stroke recurrence. Stroke 2007; 38: 458.
20. Oei HH, van deer Meer J, Hofman A, Koudstaal PJ, Stijnen T, Breteler MM, Witteman JC: Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation 2005; 111: 570-575. (Pubitemid 40216483)
21. Wassertheil-Smoller S, Kooperberg C, Mc- Ginn AP, Kaplan RC, Hsia J, Hendrix SL, Manson JE, Berger JS, Kuller LH, Allison MA, Baird AE: Lipoprotein-associated phospholipase A2, hormone use, and the risk of ischemic stroke in postmenopausal women. Hypertension 2008; 51: 1115-1122. (Pubitemid 351398957)
22. Lp-PLA2 Studies Collaboration, Thompson A, Gao P, Orfei L, Watson S, Di Angelantonio E, Kaptoge S, Ballantyne C, Cannon CP, Criqui M, Cushman M, Hofman A, Packard C, Thompson SG, Collins R, Danesh J: Lipoprotein- associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010; 375: 1536-1544.
23. Sheehan OC, Kyne L, Kelly LA, Hannon N, Marnane M, Merwick A, McCormack PM, Duggan J, Moore A, Moroney J, Daly L, Harris D, Horgan G, Williams EB, Kelly PJ: Population- based study of ABCD2 score, carotid stenosis, and atrial fibrillation for early stroke prediction after transient ischemic attack. The North Dublin TIA study. Stroke 2010; 41: 844-850.
24. Giles MF, Rothwell PM: Systematic review and pooled analysis of published and unpublished validations of the ABCD and ABCD2 transient ischemic attack risk scores. Stroke 2010; 41: 667-673.
25. Hatoum IJ, Nelson JJ, Cook NR, Hu FB, Rimm EB: Dietary, lifestyle, and clinical predictors of lipoprotein-associated phospholipase A2 in individuals without coronary heart disease. Am J Clin Nutr 2010; 91: 786-939.
26. Elkind MSV, Tai W, Coates K, Paik MC, Sacco RL: Lipoprotein-associated phospholipase A2 activity and risk of recurrent stroke. Cerebrovasc Dis 2009; 27: 42-50.
27. Massot A, Pelegrí D, Penalba A, Arenillas J, Boada C, Giralt D, Ribó M, Molina CA, Rosell A, Álvarez-Sabín j, Chacón P, Rovira A, Delgado P, Montaner J: Lipoprotein-associated phospholipase A2 testing usefulness among patients with symptomatic intracranial atherosclerotic disease. Atherosclerosis 2011; 218: 181-187.
28. Wilensky RL, Shi Y, Mohler ER III, Hamamdzic D, Burgert ME, Li J, Postle A, Fenning RS, Bollinger JG, Hoffman BE, Yang J, Mirabile RC, Webb CL, Zhang L, Zhang P, Gelb MH, Walker MC, Zalewski A, McPhee CH: Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med 2008; 14: 1059-1066.
29. Elkind MS, Leon V, Moon YP, Paik MC, Sacco RL: High-sensitivity C-reactive protein and lipoprotein-associated phospholipase A2 stability before and after stroke and myocardial infarction. Stroke 2010; 40: 3233- 3237.